These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11724310)

  • 1. Antitumor activity of cytotropic heterogeneous molecular lipids (CHML) on human breast cancer xenograft in nude mice.
    Zhan Q; Zhao SC; Xu Z
    Anticancer Res; 2001; 21(4A):2477-82. PubMed ID: 11724310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHML suppresses cell growth and induces apoptosis in multiple human tumor lines.
    Zhan Q; Xu Z
    Anticancer Res; 1999; 19(4B):2893-9. PubMed ID: 10652570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft.
    Bandyopadhyay A; López-Casillas F; Malik SN; Montiel JL; Mendoza V; Yang J; Sun LZ
    Cancer Res; 2002 Aug; 62(16):4690-5. PubMed ID: 12183427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer.
    Foster PA; Chander SK; Parsons MF; Newman SP; Woo LW; Potter BV; Reed MJ; Purohit A
    Breast Cancer Res Treat; 2008 Sep; 111(1):129-38. PubMed ID: 17914670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
    Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
    Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model.
    Kang HJ; Lee SH; Price JE; Kim LS
    Breast J; 2009; 15(3):223-9. PubMed ID: 19645775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of ZGDHu-1 on proliferation and apoptosis of A549 cells in vitro and antitumor activity in vivo].
    Zhou YL; Hu WX; Lü YP; Qiu LN; Wang WS; Yang ZY; Liu JD; Rao GW
    Yao Xue Xue Bao; 2007 Jan; 42(1):26-34. PubMed ID: 17520803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-prostate cancer and anti-breast cancer activities of two peptides derived from alpha-fetoprotein.
    Caceres G; Dauphinee MJ; Eisele LE; MacColl R; Mizejewski GJ
    Anticancer Res; 2002; 22(5):2817-20. PubMed ID: 12530002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of chemosensitivity against a human breast cancer xenograft (MX-1) with the subrenal capsule assay in BDF1 mice].
    Inoue K; Wang Y; Tada A; Ueno K; Kojima K; Ogawa M
    Gan To Kagaku Ryoho; 1985 Aug; 12(8):1644-50. PubMed ID: 4026333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis.
    Jing N; Li Y; Xiong W; Sha W; Jing L; Tweardy DJ
    Cancer Res; 2004 Sep; 64(18):6603-9. PubMed ID: 15374974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
    Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
    Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
    Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
    Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels.
    Singh RP; Dhanalakshmi S; Tyagi AK; Chan DC; Agarwal C; Agarwal R
    Cancer Res; 2002 Jun; 62(11):3063-9. PubMed ID: 12036915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
    Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
    Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
    Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
    J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model.
    Mach CM; Mathew L; Mosley SA; Kurzrock R; Smith JA
    Anticancer Res; 2009 Jun; 29(6):1895-9. PubMed ID: 19528445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.